Ankylosing spondylitis

Ankylosing spondylitis

  • June 2015 •
  • 252 pages •
  • Report ID: 4035416 •
  • Format: PDF
While the ankylosing spondylitis (AS) market will see downward pressure from the arrival of biosimilar versions of key anti-tumor necrosis factor (TNF) brands, increasing patient numbers and rising prices in the US will drive positive growth during 2014–23.
This report addresses the following questions:

- Which agents do rheumatologists currently prescribe at first line?
- Which are rheumatologists’ preferred anti-TNF biologics?
- How will the availability of lower-cost biosimilars impact the sales and patient shares of the currently marketed biologics and the prospects of pipeline therapies?
- What are rheumatologists’ views on Otezlaand what role can a novel oral small molecule play in the treatment of AS?
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.